Oncology

Latest News

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com
RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

July 23rd 2025

G
In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 29th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 29th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Kavita Patel
March 1st 2021

Kavita Patel: Drug Pricing, Care Access Priorities in Federal Health Care Policy

Rose McNulty
Kavita Patel, MD, MS, FACP, a fellow at the Brookings Institution Center for Health Policy, touched on key topics in health care at the ACCC 47th Annual Meeting and Cancer Center Business Summit.
Researcher in Laboratory
February 24th 2021

Oncolytic Virus, CAR T Combination Preclinical Study Shows Activity in Solid Tumors

Rose McNulty
Loading chimeric antigen receptor (CAR) T-cells with the oncolytic virus pelareorep improved their efficacy in solid tumor mouse models in a preclinical study presented at the CAR-TCR Summit Europe 2021.
Older Woman Speaking With Doctor
February 24th 2021

Real-World Outcomes Contrast Cancer Clinical Trial Results in Medicare Patients

Rose McNulty
Pivotal cancer clinical trial data may lack generalizability in older adults with Medicare, a study published online today in JAMA Network Open found.
FDA Approves Libtayo Monotherapy for First-Line Advanced NSCLC With PD-L1 Expression
February 22nd 2021

FDA Approves Cemiplimab for First-Line Advanced NSCLC With PD-L1 Expression

Rose McNulty
The PD-1 inhibitor cemiplimab-rwlc, sold as Libtayo, was FDA approved as a monotherapy for patients with first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Donald M. Berwick, MD, MPP
February 18th 2021

Use of COTA Nodal Address Highlights Variance in Cancer Care Cost: An Interview With Donald M. Berwick, MD, MPP

Mary Caffrey
Donald M. Berwick, MD, MPP, the former CMS administrator who is president emeritus and senior fellow at the Institute for Healthcare Improvement, discusses cost variation in cancer care found through the digital classification system the COTA Nodal Address.
Anne Hubbard, MBA
February 18th 2021

Radiation Oncology’s Role in the Next Chapter of Payment Reform

Anne Hubbard, MBA
An ideal alternative payment model would reward radiation oncologists for participation in a value-based payment arrangement that grants them the freedom to make care delivery decisions based on patient needs and in accordance with clinical guidelines, says ASTRO's Anne Hubbard, MBA.
Cosela Approved for Protection Against Myelosuppression From SCLC Treatment
February 17th 2021

Cosela Approved for Protection Against Myelosuppression From SCLC Treatment

Maggie L. Shaw
The cyclin-dependent kinase 4/6 inhibitor trilaciclib (Cosela) is the first in its class to receive FDA approval as a protective agent against bone marrow loss from treatment for small cell lung cancer (SCLC).
Amy Ellis, Northwest Medical Specialties
February 17th 2021

Amy Ellis: There Was a Big Shift to Telemedicine in Cancer Care Delivery

With the onset of the pandemic, the increased use of telemedicine has been the biggest change to how cancer care is being delivered; however, whether telemedicine is here to stay depends on the regulators and payers, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Flying the Plane While You Build It
February 16th 2021

Flying the Plane While You Build It

Joseph Alvarnas, MD
In this issue of Evidence-Based Oncology™ we see a foreshadowing of what the future of cancer care innovation could look like and how we may learn to move forward, safely, at an ever-accelerating pace.
DNA Analysis
February 10th 2021

Liquid Biopsy Demonstrates Clinical Utility in Advanced Prostate Cancer

Rose McNulty
A new study assessed the genomic alterations identified by ctDNA analysis compared with tissue-based comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.
Amy Ellis, Northwest Medical Specialties
February 3rd 2021

Amy Ellis on the Benefits of ePROs in Cancer Care

Electronic patient-reported outcomes (ePROs) tools can benefit patients by keeping them on treatment longer, and the pandemic has likely accelerated how many practices move to using ePROs, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Amy Ellis, Northwest Medical Specialties
January 22nd 2021

Amy Ellis Discusses Setting Up an ePRO Tool at a Community Cancer Center

Setting up a new tool to capture electronic patient-reported outcomes (ePROs) requires a lot of prep work to ensure patients are comfortable and ready to use the tool, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Sibel Blau, MD, Northwest Medical Specialties, Quality Cancer Care Alliance
January 18th 2021

Dr Sibel Blau Discusses Adapting to Telehealth in Oncology and Future Issues

Adapting to telehealth was not difficult, but practice transformation around telehealth has been more difficult, and there remains the future uncertainty around continued reimbursement, said Sibel Blau, MD, of Northwest Medical Specialties and Quality Cancer Care Alliance.
Sibel Blau, MD, Northwest Medical Specialties, Quality Cancer Care Alliance
January 12th 2021

Dr Sibel Blau Discusses the Impact of Delayed Cancer Diagnoses on Community Cancer Practices

Telehealth is helpful, but it is not enough to make up for the delay in cancer diagnoses occurring as a result of the pandemic, said Sibel Blau, MD, of Northwest Medical Specialties and Quality Cancer Care Alliance.
Here's your email
January 8th 2021

What We’re Reading: AHA Wants Faster Vaccine Rollout; Cancer Effect on Hearts; Teen Opioid Access

AJMC Staff
The American Hospital Association (AHA) asks HHS Secretary Alex Azar to expedite the rollout of coronavirus disease 2019 vaccines; CDC data show accelerated cardiac aging among cancer survivors; a study examines new targets for reducing adolescent access to opioids.
Basit Chaudhry, MD, PhD, Tuple Health
January 6th 2021

Dr Basit Chaudhry Expects CMS to Take Feedback From the Field to Improve OCF

Feedback from the field is incredibly important when participating in new payment models like the Oncology Care Model, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
The Top 5 Most-Read Oncology Stories of 2020
December 28th 2020

The Top 5 Most-Read Oncology Stories of 2020

Rose McNulty
Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care.
Mike Fazio, Archway Health
December 26th 2020

Mike Fazio on Choosing Between Oncology Care First or Another Oncology APM

Practices deciding whether to join Oncology Care First or another oncology alternative payment model (APM) will need a clear understanding of how big of a transformation they’ll need to make to their practice, said Mike Fazio.
Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment
December 24th 2020

Radiopharmaceuticals Are Showing Promise as the Next Generation of Cancer Treatment

JT Ripton
Recent major investments signal growth in an emerging therapeutic sector.
Community Oncology Alliance
December 21st 2020

COA Continues Effort to Stop Most Favored Nation Model

Rose McNulty
The Community Oncology Alliance's request includes declarations from community oncology practices detailing the anticipated ramifications should the Most Favored Nation rule become operative.
Kashyap Patel
December 15th 2020

Kashyap Patel, MD, Elected President of Community Oncology Alliance

Rose McNulty
Kashyap Patel, MD, associate editor of Evidence-Based Oncology, a publication of The American Journal of Managed Care, will serve a 1-year term beginning in January.
Basit Chaudhry, MD, PhD, Tuple Health
December 14th 2020

Dr Basit Chaudhry: How Practices Can Take Advantage of the Delay to Oncology Care First

With the start of Oncology Care First (OCF) being delayed, practices participating in the Oncology Care Model have more time to set themselves up to success when they transition to OCF, said Basit Chaudhry, MD, PhD, founder of Tuple Health.
Mike Fazio, Archway Health
December 9th 2020

Mike Fazio Discusses Data Lag Challenges in OCM and OCF

Throughout the Oncology Care Model (OCM), practices have dealt with a data lag, but in Oncology Care First (OCF) data is expected to be released more frequently, said Mike Fazio, of Archway Health.
Changes in Health Care
December 8th 2020

ASCO Releases Recommendations for Postpandemic Cancer Care

Rose McNulty
The American Society of Clinical Oncology calls on government bodies and the health care community to guide the cancer community’s post-pandemic recovery.
Adolescent and Young Adult Cancer
December 3rd 2020

AYA Cancer Rates Are Rising, New Study Finds

Rose McNulty
A new study published in JAMA Network Open found that the rate of cancer in adolescents and young adults increased by nearly 30% from 1973 to 2015.
Sara L. Douglas, PhD, RN, Frances Payne Bolton School of Nursing, Case Western Reserve University
December 3rd 2020

Dr Sara Douglas: Support Is Often Hard to Come By for Distance Caregivers

Distance caregivers of patients with cancer often find it difficult to enlist adequate support, noted Sara L. Douglas, PhD, RN, associate dean for research at the Frances Payne Bolton School of Nursing at Case Western Reserve University.
Randall Oyer, MD, president of the Association of Community Cancer Centers
November 24th 2020

Dr Randall Oyer on ACCC and ASCO's Work to Reduce Clinical Trial Disparities

Rose McNulty
Randall Oyer, MD, president of the Association of Community Cancer Centers, discusses the ACCC and American Society of Clinical Oncology's initiative to make clinical trials more inclusive.
Using Data to Drive Practice
November 20th 2020

How US Oncology Network Practices Find Success in the OCM

Rose McNulty
The Network enrolled its 100,000th patient in the Oncology Care Model (OCM) recently, and its practices are finding success in the complicated model.
Dr Karen Winkfield
November 17th 2020

Dr Karen Winkfield Discusses Importance of Workforce Diversity in Oncology

Representation of minority populations in the oncology workforce is important to educate physicians on the meaning of being culturally appropriate, and to provide culturally appropriate care.
Doctor Looking at Scan
November 12th 2020

Medicaid Expansion Associated With More Early-Stage Cancer Diagnoses

Rose McNulty
Data in a new analysis showed that Medicaid expansion under the Affordable Care Act had positive effects on rates of early-stage cancer diagnosis, and the results were immediate.
<1
...
171819202122232425
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo